US HB4241 | 2013-2014 | 113th Congress
Status
Spectrum: Moderate Partisan Bill (Democrat 15-4)
Status: Introduced on March 13 2014 - 25% progression, died in committee
Action: 2014-03-14 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on March 13 2014 - 25% progression, died in committee
Action: 2014-03-14 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Act to Ban Zohydro - Ends the sale and distribution of pure hydrocodone bitartrate extended-release capsules (marketed as Zohydro ER) within 45 days by withdrawing approval for its new drug application. Prohibits the Commissioner of Food and Drugs (FDA) from approving any new drug application for the capsules unless they are formulated to prevent abuse.
Title
Act to Ban Zohydro
Sponsors
| Rep. Stephen Lynch [D-MA] | Rep. Earl Blumenauer [D-OR] | Rep. Michael Capuano [D-MA] | Rep. Katherine Clark [D-MA] |
| Rep. Rosa DeLauro [D-CT] | Rep. Michael Fitzpatrick [R-PA] | Rep. Michael Grimm [R-NY] | Rep. Brian Higgins [D-NY] |
| Rep. William Keating [D-MA] | Rep. Joseph Kennedy [D-MA] | Rep. Michael Michaud [D-ME] | Rep. Harold Rogers [R-KY] |
| Rep. Janice Schakowsky [D-IL] | Rep. Carol Shea-Porter [D-NH] | Rep. Jackie Speier [D-CA] | Rep. John Tierney [D-MA] |
| Rep. Paul Tonko [D-NY] | Sen. Peter Welch [D-VT] | Rep. Frank Wolf [R-VA] |
History
| Date | Chamber | Action |
|---|---|---|
| 2014-03-14 | House | Referred to the Subcommittee on Health. |
| 2014-03-13 | House | Referred to the House Committee on Energy and Commerce. |
Same As/Similar To
SB2134 (Same As) 2014-03-13 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Subjects
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/113th-congress/house-bill/4241/all-info |
| Text | https://www.congress.gov/113/bills/hr4241/BILLS-113hr4241ih.pdf |
